Please select the option that best describes you:

Do you recommend trilaciclib as primary prophylaxis for myelosuppression in certain patients with ES-SCLC treated with first line chemo-immunotherapy?   



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more